TriSalus Life Sciences (TLSI) to Release Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) is projected to release its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect TriSalus Life Sciences to post earnings of ($0.13) per share and revenue of $13.20 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

TriSalus Life Sciences Stock Performance

Shares of TLSI opened at $4.94 on Wednesday. The business’s 50-day moving average is $5.50 and its two-hundred day moving average is $5.37. The company has a market capitalization of $247.30 million, a P/E ratio of -2.45 and a beta of 0.42. TriSalus Life Sciences has a fifty-two week low of $3.42 and a fifty-two week high of $7.95.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Zacks Research upgraded TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Wall Street Zen lowered shares of TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. Finally, Canaccord Genuity Group increased their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences presently has a consensus rating of “Hold” and a consensus price target of $12.00.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC boosted its stake in shares of TriSalus Life Sciences by 1.5% in the fourth quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock valued at $14,454,000 after purchasing an additional 30,582 shares during the period. Vanguard Group Inc. lifted its holdings in TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after buying an additional 345,186 shares in the last quarter. Gilder Gagnon Howe & Co. LLC boosted its position in TriSalus Life Sciences by 32.1% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after buying an additional 265,618 shares during the period. Geode Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 35.5% in the fourth quarter. Geode Capital Management LLC now owns 751,207 shares of the company’s stock worth $5,245,000 after acquiring an additional 196,752 shares in the last quarter. Finally, State Street Corp grew its stake in shares of TriSalus Life Sciences by 37.4% in the fourth quarter. State Street Corp now owns 264,628 shares of the company’s stock worth $1,847,000 after acquiring an additional 71,995 shares in the last quarter. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.